Doctor of Law and Policy (L.P.D.)

Law and Policy
Northeastern University
2012

Master of Business Administration (M.B.A.)

Business Administration
Loyola University
2000

Bachelor of Science (B.Sc.)

Pharmacy
Howard University
1991

Pharmacy Management, Pharmaceutical Law & Policy, Pharmacy Operations, Research, Pharmacogenomics & Policy, Business, Strategic Planning, Regulatory Affairs, Talent Development

Principles of Pharmacy Administration

This course is an expansive and in-depth Introduction to Pharmacy Administration. It facilitates the student’s management and leadership training by introducing them to a comprehensive overview of management and leadership principles, concepts and practices in pharmacy-based environments. The course further addresses the economic, administrative, entrepreneurial, innovative and human resource aspects of pharmacy practice while furthering students’ knowledge on details about the US Health Care System from a pharmacist perspective.

Pharmacy Care Management

This course is an expansive and in-depth exploration of Pharmacy Care Management within the US healthcare system. It facilitates the graduate student’s management and leadership training by introducing them to a comprehensive overview of management and leadership principles, concepts and practices in pharmacy based environments. The course further addresses the social, organizational and economic aspects of healthcare delivery while allowing the student to model real world applications. 

Making Medicines

“Making Medicines: The Process of Drug Development” is an eLearning course in collaboration with a team of academic leaders designed to deliver a scientific education curriculum highlighting the fundamental processes and rigor drug manufacturers undertake to research, develop, and deliver new medicines to patients. In this course, you will explore how a new drug is developed from the initial concept to the patient. The goal of the course is to provide an opportunity for individuals with an interest in a health-related field and medical research to learn the processes required to discover and develop drugs, that will ultimately provide a benefit to meet unmet medical needs, with minimal risk. 

Pharmacy Jurisprudence

This course involves an examination of the laws and regulatory issues pertaining to the practice of pharmacy.  Specifically, the course will focus on pertinent sections of the federal Controlled Substances Act, Food Drug and Cosmetic Act and other federal law, as well as an overview of pharmacy laws applicable in the District of Columbia, Maryland, and Virginia.  The course is designed to assist students in preparing for and passing the MPJE. 

Pharmacy Law and Policy

This is a survey course in U.S. Pharmaceutical and Health policy and law. It begins by describing the basic machinery of policymaking and legal process that underpin the individual health care and public health systems and then turns to an exploration of many of the fundamental problems and contemporary issues in pharmaceutical/health policy and law.

Chauncey I Cooper, Distinguished Alumnus Award for Outstanding Service in Pharmacy & Healthcare

Cardinal Health Generation Rx Champions Award

Washington D.C. Pharmacists Association (WDCPhA), 2018

Most Outstanding Presentation in the Area of Translational & Clinical Sciences in the Junior Faculty Category Award. Research Symposium Howard University.

Research Symposium, Howard University, 2017

Howard University College of Pharmacy Alumni Legacy by Decades" Award

Best Overall Poster Presentation

Advancing Computational Biology Symposium, Gallaudet University, 2016

Most Outstanding Presentation by a Junior Faculty Researcher

Howard University Research Day, 2014

Paragon Award for Operational Excellence

CVS/Caremark, 2005

Excellence in Execution Award

CVS/Caremark, 2003

Trailblazer Award

National Press Club, 2000

Howard Bovell Excellence in Pharmacy Award

Howard University College of Pharmacy, 1991

Upjohn Pharmaceutical Sciences Award

Howard University College of Pharmacy, 1991

Mylan Pharmaceuticals Excellence in Pharmacy Award

Howard University College of Pharmacy, 1991

Disorders of gut-brain interaction are a new challenge of our increasingly complex society

Disorders of gut-brain interaction are a new challenge of our increasingly complex society, with worldwide repercussions

The term disorders of gut-brain interaction (DGBIs) encompasses gastrointestinal disorders that globally affect more than one third of all people. The Rome IV criteria replaced the former term “functional gastrointestinal disorders.“ DGBIs can seriously challenge health and quality of life (QoL). A traditional but outdated approach differentiated “organic” vs “functional“ disorders, seen by some as real vs psychiatric or undefined ones. This traditional distinction did not help patients whose health and QoL are seriously affected. DGBIs include motility disturbance; visceral hypersensitivity; altered mucosal and immune function; altered central nervous system processing, and more. Several DGBIs affect both children and adolescents.

African minors’ health challenges are comparable to those in the rest of the world

African minors’ health challenges are comparable to those in the rest of the world

Today’s youth in rich and poor countries faces comparable health risks and challenges. There is the temptation to enjoy too much food that is advertised as delicious and to eat too little healthier food. An increasingly sedentary lifestyle makes physical activity voluntary, no longer based on the daily need for physical activity in rural production. This is a serious medical problem, as today’s young people are threatened tomorrow (and sometimes, already today) by cardiovascular disease and type 2 diabetes mellitus, later by further challenges including arthritis, stroke, and more. But this is a challenge far beyond medicine. Young people need to be empowered to distinguish between good and bad lifestyles and be strengthened in their willingness to make an effort for future health.

Factors and Disparities Influencing Sodium-Glucose

Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence

Health disparities affecting minority populations and resulting in poorer outcomes for disadvantaged groups have been documented in the literature. Sodium/glucose-cotransporter 2 (SGLT2i) inhibitors and GLP-1 receptor agonists (GLP-1RA) markedly decrease mortality from kidney and cardiovascular events. However, little is known about the factors and disparities that lead to differences in SGLT2i and GLP-1RA initiation across different ethnic groups. Methods: This scoping review queried databases using key terms related to disparities in the initiation of SGLT2i and GLP-1RA among high-risk populations.

Melanoma and pediatric drug development

Melanoma and pediatric drug development: clinical progress vs. regulatory activism in minors - a narrative review

Melanoma is the malignancy where, in recent years, drug treatment has massively improved prognosis and quality of life. Based on genetic analysis, we differentiate today melanomas caused by cumulative solar damage (CSD) from others.

Predictors of Using Pharmacists as a Medication Safety Information Resource Among Women of Reproductive Age

Predictors of Using Pharmacists as a Medication Safety Information Resource Among Women of Reproductive Age

Medication use during pregnancy is prevalent with notable increases in the use of over-the-counter medications. In this era of information proliferation, it is important to understand where women of reproductive age obtain information on medication safety.

The main objective of this study was to determine the predictive factors associated with the utilization of pharmacists as a medication information safety resource among reproductive age women.

Deception and Fraud in the Justification of "Pediatric Drug Development"

Deception and Fraud in the Justification of "Pediatric Drug Development": A Challenge at the Interface of Medicine and Law

United States and European Union laws demand separate clinical studies in children as a condition for drugs' marketing approval. Justified by carefully framed pseudo-scientific wordings, more so the European Medicines Agency than the United States Food and Drug Administration, "Pediatric Drug Development" is probably the largest abuse in medical research in history. Preterm newborns are immature and vulnerable, but they grow. Adolescents are bodily no longer children. Younger children are not another species. Instead of reasonable dose-finding, most "pediatric" studies replicate at best what is known already; others withhold effective treatment and/or harm by substandard comparison, triggering "pediatric" drug labels and "pediatric" careers. Researching deception and fraud focuses currently on individuals. The mechanisms by which lawmakers and the public were and are deceived need elucidation in our increasingly complex society, including new types of conflicts of interest. Candidly addressing deception and fraud at the interface of medicine and law will help to unmask pseudoscience.

Pharmacogenomics and pediatric drug development

Pharmacogenomics and pediatric drug development: science and political power. A narrative review

Pharmacogenomics (PGx) investigates how genomes control enzyme expression. Developmental pharmacology (DP) describes the temporal sequence of enzymes impacting absorption, distribution, metabolism, and excretion (ADME) of food and drugs.

US and European Union (EU) legislation facilitate and/or enforce pediatric studies for all new drugs, called overall ‘pediatric drug development’ (PDD). DP and PDD look at patients’ chronological age, but oscillate between legal and physiological meanings of the term ‘child.’ Children’s bodies become mature with puberty.

Decades after first DP observations in babies, PGx offers a better understanding of the variability of safety and efficacy of drugs, of the process of aging, and of shifting enzyme patterns across aging. We should rethink and revise outdated interpretations of ADME changes in minors. The Declaration of Helsinki forbids pointless studies that some pediatric researchers and regulatory agencies, more so the EMA than the FDA, demand pointless pediatric studies is regrettable. Medicine needs to differentiate between legal and physiological meanings of the term ‘child’ and should use objective measures of maturity.

National trends in reported past year opioid misuse among black women

National trends in reported past year opioid misuse among black women

The opioid crisis within the United States has been widely studied; however, some gaps within the literature still exist. There is limited information on trends in opioid misuse as it relates to income among a national sample of Black Women. Given the recent increase in opioid overdose deaths in Black Americans and the vulnerability of women who misuse opioids, research in this population is important.

The objective of this study is to evaluate trends of past year opioid misuse (PYOM) among Black women by income over the study period.